ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Research Report 2025
Published Date: March 2025
|
Report Code: QYRE-Auto-25Y12554
Home | Market Reports | Health| Aging & Geriatrics
Global Neurological Biomarkers for Alzheimer s and Parkinson s Diseases Market Research Report 2022
BUY CHAPTERS

Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Research Report 2025

Code: QYRE-Auto-25Y12554
Report
March 2025
Pages:100
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
AbaStar MDx
Abbott Laboratories
Abiant
Acumen pharmaceuticals
Alseres Pharmaceuticals
Athena Diagnostics
Banyan Biomarkers
Bio Rad Laboratories
Diagenic Asa
ImmunArray
Myriad RBM
Proteome Sciences
Qiagen NV
Thermo Fisher Scientific
ProteoSys AG
Psynova Neurotech
Quanterix Corporation

Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market

The global market for Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases include AbaStar MDx, Abbott Laboratories, Abiant, Acumen Pharmaceuticals, Alseres Pharmaceuticals, Athena Diagnostics, Banyan Biomarkers, Bio-Rad Laboratories, Diagenic ASA, Immunarray Pvt, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases.
The Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Report

Report Metric Details
Report Name Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market
Segment by Type
  • Genome
  • Proteome
Segment by Application
  • Hospital Laboratories
  • Research Organizations
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company AbaStar MDx, Abbott Laboratories, Abiant, Acumen Pharmaceuticals, Alseres Pharmaceuticals, Athena Diagnostics, Banyan Biomarkers, Bio-Rad Laboratories, Diagenic ASA, Immunarray Pvt, Myriad RBM, Proteome Sciences, ProteoSys AG, Psynova Neurotech, Qiagen, Quanterix Corporation, Thermo Fisher Scientific
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market report?

Ans: The main players in the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market are AbaStar MDx, Abbott Laboratories, Abiant, Acumen Pharmaceuticals, Alseres Pharmaceuticals, Athena Diagnostics, Banyan Biomarkers, Bio-Rad Laboratories, Diagenic ASA, Immunarray Pvt, Myriad RBM, Proteome Sciences, ProteoSys AG, Psynova Neurotech, Qiagen, Quanterix Corporation, Thermo Fisher Scientific

What are the Application segmentation covered in the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market report?

Ans: The Applications covered in the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market report are Hospital Laboratories, Research Organizations, Others

What are the Type segmentation covered in the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market report?

Ans: The Types covered in the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market report are Genome, Proteome

1 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Overview
1.1 Product Definition
1.2 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Type
1.2.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Value Comparison by Type (2024 VS 2031)
1.2.2 Genome
1.2.3 Proteome
1.3 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Application
1.3.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Value by Application (2024 VS 2031)
1.3.2 Hospital Laboratories
1.3.3 Research Organizations
1.3.4 Others
1.4 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Estimates and Forecasts
1.4.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue 2020-2031
1.4.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales 2020-2031
1.4.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Competition by Manufacturers
2.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Manufacturers (2020-2025)
2.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases, Product Type & Application
2.7 Global Key Manufacturers of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases, Date of Enter into This Industry
2.8 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Competitive Situation and Trends
2.8.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Players Market Share by Revenue
2.8.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Scenario by Region
3.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region: 2020-2031
3.2.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region: 2020-2025
3.2.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region: 2026-2031
3.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Region: 2020-2031
3.3.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Region: 2020-2025
3.3.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Region: 2026-2031
3.4 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Facts & Figures by Country
3.4.1 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country (2020-2031)
3.4.3 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Facts & Figures by Country
3.5.1 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country (2020-2031)
3.5.3 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Facts & Figures by Region
3.6.1 Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region (2020-2031)
3.6.3 Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Facts & Figures by Country
3.7.1 Latin America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country (2020-2031)
3.7.3 Latin America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Facts & Figures by Country
3.8.1 Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country (2020-2031)
3.8.3 Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Type (2020-2031)
4.1.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Type (2020-2025)
4.1.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Type (2026-2031)
4.1.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Type (2020-2031)
4.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Type (2020-2031)
4.2.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Type (2020-2025)
4.2.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Type (2026-2031)
4.2.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Type (2020-2031)
4.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Price by Type (2020-2031)
5 Segment by Application
5.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Application (2020-2031)
5.1.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Application (2020-2025)
5.1.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Application (2026-2031)
5.1.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Application (2020-2031)
5.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Application (2020-2031)
5.2.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Application (2020-2025)
5.2.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Application (2026-2031)
5.2.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Application (2020-2031)
5.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Price by Application (2020-2031)
6 Key Companies Profiled
6.1 AbaStar MDx
6.1.1 AbaStar MDx Company Information
6.1.2 AbaStar MDx Description and Business Overview
6.1.3 AbaStar MDx Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales, Revenue and Gross Margin (2020-2025)
6.1.4 AbaStar MDx Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Portfolio
6.1.5 AbaStar MDx Recent Developments/Updates
6.2 Abbott Laboratories
6.2.1 Abbott Laboratories Company Information
6.2.2 Abbott Laboratories Description and Business Overview
6.2.3 Abbott Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Abbott Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Portfolio
6.2.5 Abbott Laboratories Recent Developments/Updates
6.3 Abiant
6.3.1 Abiant Company Information
6.3.2 Abiant Description and Business Overview
6.3.3 Abiant Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Abiant Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Portfolio
6.3.5 Abiant Recent Developments/Updates
6.4 Acumen Pharmaceuticals
6.4.1 Acumen Pharmaceuticals Company Information
6.4.2 Acumen Pharmaceuticals Description and Business Overview
6.4.3 Acumen Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Acumen Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Portfolio
6.4.5 Acumen Pharmaceuticals Recent Developments/Updates
6.5 Alseres Pharmaceuticals
6.5.1 Alseres Pharmaceuticals Company Information
6.5.2 Alseres Pharmaceuticals Description and Business Overview
6.5.3 Alseres Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Alseres Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Portfolio
6.5.5 Alseres Pharmaceuticals Recent Developments/Updates
6.6 Athena Diagnostics
6.6.1 Athena Diagnostics Company Information
6.6.2 Athena Diagnostics Description and Business Overview
6.6.3 Athena Diagnostics Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Athena Diagnostics Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Portfolio
6.6.5 Athena Diagnostics Recent Developments/Updates
6.7 Banyan Biomarkers
6.7.1 Banyan Biomarkers Company Information
6.7.2 Banyan Biomarkers Description and Business Overview
6.7.3 Banyan Biomarkers Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Banyan Biomarkers Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Portfolio
6.7.5 Banyan Biomarkers Recent Developments/Updates
6.8 Bio-Rad Laboratories
6.8.1 Bio-Rad Laboratories Company Information
6.8.2 Bio-Rad Laboratories Description and Business Overview
6.8.3 Bio-Rad Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Bio-Rad Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Portfolio
6.8.5 Bio-Rad Laboratories Recent Developments/Updates
6.9 Diagenic ASA
6.9.1 Diagenic ASA Company Information
6.9.2 Diagenic ASA Description and Business Overview
6.9.3 Diagenic ASA Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Diagenic ASA Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Portfolio
6.9.5 Diagenic ASA Recent Developments/Updates
6.10 Immunarray Pvt
6.10.1 Immunarray Pvt Company Information
6.10.2 Immunarray Pvt Description and Business Overview
6.10.3 Immunarray Pvt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Immunarray Pvt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Portfolio
6.10.5 Immunarray Pvt Recent Developments/Updates
6.11 Myriad RBM
6.11.1 Myriad RBM Company Information
6.11.2 Myriad RBM Description and Business Overview
6.11.3 Myriad RBM Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Myriad RBM Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Portfolio
6.11.5 Myriad RBM Recent Developments/Updates
6.12 Proteome Sciences
6.12.1 Proteome Sciences Company Information
6.12.2 Proteome Sciences Description and Business Overview
6.12.3 Proteome Sciences Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Proteome Sciences Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Portfolio
6.12.5 Proteome Sciences Recent Developments/Updates
6.13 ProteoSys AG
6.13.1 ProteoSys AG Company Information
6.13.2 ProteoSys AG Description and Business Overview
6.13.3 ProteoSys AG Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales, Revenue and Gross Margin (2020-2025)
6.13.4 ProteoSys AG Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Portfolio
6.13.5 ProteoSys AG Recent Developments/Updates
6.14 Psynova Neurotech
6.14.1 Psynova Neurotech Company Information
6.14.2 Psynova Neurotech Description and Business Overview
6.14.3 Psynova Neurotech Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Psynova Neurotech Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Portfolio
6.14.5 Psynova Neurotech Recent Developments/Updates
6.15 Qiagen
6.15.1 Qiagen Company Information
6.15.2 Qiagen Description and Business Overview
6.15.3 Qiagen Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Qiagen Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Portfolio
6.15.5 Qiagen Recent Developments/Updates
6.16 Quanterix Corporation
6.16.1 Quanterix Corporation Company Information
6.16.2 Quanterix Corporation Description and Business Overview
6.16.3 Quanterix Corporation Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Quanterix Corporation Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Portfolio
6.16.5 Quanterix Corporation Recent Developments/Updates
6.17 Thermo Fisher Scientific
6.17.1 Thermo Fisher Scientific Company Information
6.17.2 Thermo Fisher Scientific Description and Business Overview
6.17.3 Thermo Fisher Scientific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Thermo Fisher Scientific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Portfolio
6.17.5 Thermo Fisher Scientific Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Industry Chain Analysis
7.2 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production Mode & Process Analysis
7.4 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales and Marketing
7.4.1 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Channels
7.4.2 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Distributors
7.5 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Customer Analysis
8 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Dynamics
8.1 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Industry Trends
8.2 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Drivers
8.3 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Challenges
8.4 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
AbaStar MDx
Abbott Laboratories
Abiant
Acumen pharmaceuticals
Alseres Pharmaceuticals
Athena Diagnostics
Banyan Biomarkers
Bio Rad Laboratories
Diagenic Asa
ImmunArray
Myriad RBM
Proteome Sciences
Qiagen NV
Thermo Fisher Scientific
ProteoSys AG
Psynova Neurotech
Quanterix Corporation
List of Tables
 Table 1. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases, Product Type & Application
 Table 12. Global Key Manufacturers of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region (2020-2025) & (K Units)
 Table 18. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Region (2020-2025)
 Table 19. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region (2026-2031) & (K Units)
 Table 20. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Region (2026-2031)
 Table 21. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Region (2020-2025)
 Table 23. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Region (2026-2031)
 Table 25. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country (2020-2025) & (K Units)
 Table 27. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country (2026-2031) & (K Units)
 Table 28. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units) by Type (2020-2025)
 Table 51. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units) by Type (2026-2031)
 Table 52. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Type (2020-2025)
 Table 53. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Type (2026-2031)
 Table 54. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Type (2020-2025)
 Table 57. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Type (2026-2031)
 Table 58. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units) by Application (2020-2025)
 Table 61. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units) by Application (2026-2031)
 Table 62. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Application (2020-2025)
 Table 63. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Application (2026-2031)
 Table 64. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Application (2020-2025)
 Table 67. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Application (2026-2031)
 Table 68. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Price (US$/Unit) by Application (2026-2031)
 Table 70. AbaStar MDx Company Information
 Table 71. AbaStar MDx Description and Business Overview
 Table 72. AbaStar MDx Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. AbaStar MDx Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product
 Table 74. AbaStar MDx Recent Developments/Updates
 Table 75. Abbott Laboratories Company Information
 Table 76. Abbott Laboratories Description and Business Overview
 Table 77. Abbott Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Abbott Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product
 Table 79. Abbott Laboratories Recent Developments/Updates
 Table 80. Abiant Company Information
 Table 81. Abiant Description and Business Overview
 Table 82. Abiant Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Abiant Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product
 Table 84. Abiant Recent Developments/Updates
 Table 85. Acumen Pharmaceuticals Company Information
 Table 86. Acumen Pharmaceuticals Description and Business Overview
 Table 87. Acumen Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Acumen Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product
 Table 89. Acumen Pharmaceuticals Recent Developments/Updates
 Table 90. Alseres Pharmaceuticals Company Information
 Table 91. Alseres Pharmaceuticals Description and Business Overview
 Table 92. Alseres Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Alseres Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product
 Table 94. Alseres Pharmaceuticals Recent Developments/Updates
 Table 95. Athena Diagnostics Company Information
 Table 96. Athena Diagnostics Description and Business Overview
 Table 97. Athena Diagnostics Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Athena Diagnostics Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product
 Table 99. Athena Diagnostics Recent Developments/Updates
 Table 100. Banyan Biomarkers Company Information
 Table 101. Banyan Biomarkers Description and Business Overview
 Table 102. Banyan Biomarkers Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Banyan Biomarkers Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product
 Table 104. Banyan Biomarkers Recent Developments/Updates
 Table 105. Bio-Rad Laboratories Company Information
 Table 106. Bio-Rad Laboratories Description and Business Overview
 Table 107. Bio-Rad Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Bio-Rad Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product
 Table 109. Bio-Rad Laboratories Recent Developments/Updates
 Table 110. Diagenic ASA Company Information
 Table 111. Diagenic ASA Description and Business Overview
 Table 112. Diagenic ASA Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Diagenic ASA Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product
 Table 114. Diagenic ASA Recent Developments/Updates
 Table 115. Immunarray Pvt Company Information
 Table 116. Immunarray Pvt Description and Business Overview
 Table 117. Immunarray Pvt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Immunarray Pvt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product
 Table 119. Immunarray Pvt Recent Developments/Updates
 Table 120. Myriad RBM Company Information
 Table 121. Myriad RBM Description and Business Overview
 Table 122. Myriad RBM Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. Myriad RBM Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product
 Table 124. Myriad RBM Recent Developments/Updates
 Table 125. Proteome Sciences Company Information
 Table 126. Proteome Sciences Description and Business Overview
 Table 127. Proteome Sciences Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Proteome Sciences Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product
 Table 129. Proteome Sciences Recent Developments/Updates
 Table 130. ProteoSys AG Company Information
 Table 131. ProteoSys AG Description and Business Overview
 Table 132. ProteoSys AG Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. ProteoSys AG Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product
 Table 134. ProteoSys AG Recent Developments/Updates
 Table 135. Psynova Neurotech Company Information
 Table 136. Psynova Neurotech Description and Business Overview
 Table 137. Psynova Neurotech Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 138. Psynova Neurotech Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product
 Table 139. Psynova Neurotech Recent Developments/Updates
 Table 140. Qiagen Company Information
 Table 141. Qiagen Description and Business Overview
 Table 142. Qiagen Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 143. Qiagen Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product
 Table 144. Qiagen Recent Developments/Updates
 Table 145. Quanterix Corporation Company Information
 Table 146. Quanterix Corporation Description and Business Overview
 Table 147. Quanterix Corporation Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 148. Quanterix Corporation Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product
 Table 149. Quanterix Corporation Recent Developments/Updates
 Table 150. Thermo Fisher Scientific Company Information
 Table 151. Thermo Fisher Scientific Description and Business Overview
 Table 152. Thermo Fisher Scientific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 153. Thermo Fisher Scientific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product
 Table 154. Thermo Fisher Scientific Recent Developments/Updates
 Table 155. Key Raw Materials Lists
 Table 156. Raw Materials Key Suppliers Lists
 Table 157. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Distributors List
 Table 158. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Customers List
 Table 159. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Trends
 Table 160. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Drivers
 Table 161. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Challenges
 Table 162. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Restraints
 Table 163. Research Programs/Design for This Report
 Table 164. Key Data Information from Secondary Sources
 Table 165. Key Data Information from Primary Sources
 Table 166. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases
 Figure 2. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share by Type: 2024 & 2031
 Figure 4. Genome Product Picture
 Figure 5. Proteome Product Picture
 Figure 6. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share by Application: 2024 & 2031
 Figure 8. Hospital Laboratories
 Figure 9. Research Organizations
 Figure 10. Others
 Figure 11. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (2020-2031) & (K Units)
 Figure 14. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price (US$/Unit) & (2020-2031)
 Figure 15. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Report Years Considered
 Figure 16. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Share by Manufacturers in 2024
 Figure 17. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Players: Market Share by Revenue in Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases in 2024
 Figure 19. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Country (2020-2031)
 Figure 22. North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Country (2020-2031)
 Figure 23. United States Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Country (2020-2031)
 Figure 26. Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Region (2020-2031)
 Figure 34. China Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. China Taiwan Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Southeast Asia Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Latin America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Country (2020-2031)
 Figure 42. Latin America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Country (2020-2031)
 Figure 43. Mexico Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Brazil Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Argentina Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Country (2020-2031)
 Figure 47. Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Country (2020-2031)
 Figure 48. Turkey Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Saudi Arabia Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. UAE Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Global Sales Market Share of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Type (2020-2031)
 Figure 52. Global Revenue Market Share of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Type (2020-2031)
 Figure 53. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Price (US$/Unit) by Type (2020-2031)
 Figure 54. Global Sales Market Share of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Application (2020-2031)
 Figure 55. Global Revenue Market Share of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Application (2020-2031)
 Figure 56. Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Price (US$/Unit) by Application (2020-2031)
 Figure 57. Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Value Chain
 Figure 58. Channels of Distribution (Direct Vs Distribution)
 Figure 59. Bottom-up and Top-down Approaches for This Report
 Figure 60. Data Triangulation
 Figure 61. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

Global Alzheimer s Disease Biomarker Market Research Report 2024
Neurodegenerative Diseases Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Stroke Testing Biomarkers Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Central Nervous System Biomarkers Market Insights Forecast to 2030
Global Neurodegenerative Disease Treatment Market Research Report 2024
Neurodegenerative Diseases Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Neuroscience Antibodies and Assays Technology Market Research Report 2025
Global Alzheimers and Parkinsons Diseases Market Insights Forecast to 2030
Global Targeted Drugs for Neurodegenerative Diseases Market Research Report 2024
Global Neurodegenerative Disorder Therapeutics Market Research Report 2024
Global Nervous System Markers Market Research Report 2025
Global Neuronal Markers Market Research Report 2025
Alzheimer s Disease Diagnostic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Targeted Drugs for Parkinson s Disease Market Research Report 2024
Global Targeted Drugs for Alzheimer s Disease Market Research Report 2024
Neuroscience Medical Devices Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Imaging Biomarker Market Research Report 2025
Global Alzheimer s Drugs Market Research Report 2025
Global Brain Imaging And Neuroimaging Market Research Report 2025
Global Alzheimer s Disease Therapeutics and Diagnostics Market Insights Forecast to 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions